Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Soft Tissue Sarcomas: early-phase trial registry
2 of 2 indexed Soft Tissue Sarcomas trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 2 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Soft Tissue Sarcomas: 2 US clinical trials tracked, 2 recruiting.
Soft Tissue Sarcomas is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Vanderbilt-Ingram Cancer Center, running 1 of these trials.
Enrollment posture brief
Registry condition soft-tissue-sarcomas
OPEN 2 | RECR 100% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Soft Tissue Sarcomas lists 2 open slots (100% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Soft Tissue Sarcomas on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Soft Tissue Sarcomas is recruiting above its size-band peers.
2 of 2 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
Hypofractionated Radiotherapy Followed by Surgical Resection in the Treatment of Soft Tissue Sarcomas
Vanderbilt-Ingram Cancer Center
NCT04506008
A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions
M.D. Anderson Cancer Center
NCT06308419
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Soft Tissue Sarcomas records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Soft Tissue Sarcomas trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Soft Tissue Sarcomas page
2 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Soft Tissue Sarcomas trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Vanderbilt-Ingram Cancer Center sponsors the most Soft Tissue Sarcomas trials on record, review their full trial history before evaluating a specific study. See Vanderbilt-Ingram Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Soft Tissue Sarcomas condition card totals 2 registered trials; most-linked intervention Nab-Sirolimus; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.